ANNX vs JANX
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
ANNX · Annexon$3.10 ▼ 9.09%
JANX · Janux Therapeutics$10.08 ▼ 2.04%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- ANNX -31.3%
- JANX -68.0%
Head to head
| Metric | ANNX | JANX |
|---|---|---|
| Price | $3.10 | $10.08 |
| Change today | ▼ 9.09% | ▼ 2.04% |
| Market cap | $591.37M | $616.73M |
| Return, 3 months | -38.7% | -45.8% |
| Return, year to date | -38.2% | -27.0% |
| Return, 1 year | -27.4% | -65.0% |
| P/E (TTM) | – | – |
| P/B | 4.1 | 0.7 |
| P/E percentile vs own 5y | 28th | 88th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -7.1% |
| Net profit growth (YoY) | +6.7% | +11.3% |
| Gross margin | – | – |
| Operating margin | – | -599.3% |
| Net margin | – | -428.7% |
| Return on equity | -129.6% | -10.6% |
| Analyst target vs. price | +545.2% | +205.6% |
| Analyst buy share | 100% | 75% |
| RSI (14) | 30 | 25 |
| 30-day volatility | 81.2% | 111.2% |
| Max drawdown, 1 year | -55.5% | -71.0% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- JANX is the largest of the group by market value.
- ANNX has returned the most over the past year.
- ANNX has been the calmest stock over the last 30 days.